Back to search

Article

Extended single-dose toxicity study of [211At]meta-astatobenzylguanidine in normal mice in preparation for the first-in-human clinical trial of targeted alpha therapy for pheochromocytoma and paraganglioma

2025-04-24

Abstract excerpt

<title>Abstract</title> <p>Objective Targeted alpha-particle therapy (TAT) is promising with a greater therapeutic effect than conventional beta radionuclide therapy. To develop human clinical trials of [<sup>211</sup>At]<italic>meta</italic>-astatobenzylguanidine ([<sup>211</sup>At]MABG), we have conducted an extended single-dose toxicity study of [<sup>211</sup>At]MABG in normal mice in consultation with the P...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
03c22a4c-ae90-577e-b52d-04e9b97253dc
DOI
10.21203/rs.3.rs-6059261/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 10 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Extended single-dose toxicity study of [211At]meta-astatobenzylguanidine in normal mice in preparation for the first-in-human clinical trial of targeted alpha therapy for pheochromocytoma and paragangliomaDOI 10.21203/rs.3.rs-6059261/v1
Select a neighboring publication to make it the new centre.